Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-20

Clinical Trial Update: Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada [Phase 4]

View source ↗

Summary

Phase 4 trial update collecting blood samples from relapsing MS patients who developed ITP after Lemtrada; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lemtrada (alemtuzumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2020-07-20